IL1B and obesity disorder: SLKDT intervention significantly inhibited obesity‐induced inflammation by decreasing the proinflammatory factors IL‐6, TNF‐α, IFN‐γ, and IL‐1β and increasing the anti‐inflammatory cytokines IL‐4 and IL‐10.